Markets

The new Five Below: Kaleido Biosciences, a microbiome biotech, prices IPO at $15, $5 below the range

Kaleido Biosciences, an early-stage biotech developing oral microbiome therapies, raised $75 million by offering 5 million shares at $15, below the range of $20 to $22. The company had originally planned to raise $100 million by offering 4.8 million shares. Kaleido Biosciences plans to list on the Nasdaq under the symbol KLDO. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as lead managers on the deal.

The article The new Five Below: Kaleido Biosciences, a microbiome biotech, prices IPO at $15, $5 below the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More